Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

22.43
-1.5100-6.31%
Post-market: 22.430.00000.00%16:53 EST
Volume:1.31M
Turnover:29.69M
Market Cap:2.81B
PE:-6.82
High:23.40
Open:23.19
Low:22.20
Close:23.94
52wk High:26.40
52wk Low:6.50
Shares:125.35M
Float Shares:88.65M
Volume Ratio:0.76
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2900
EPS(LYR):-3.2900
ROE:-63.26%
ROA:-21.08%
PB:4.46
PE(LYR):-6.82

Loading ...

Arcus’ 2026 Oncology Readouts And Phase 3 Progress Might Change The Case For Investing In RCUS

Simply Wall St.
·
Jan 17

Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs

TIPRANKS
·
Jan 13

Arcus Biosciences Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Jan 08

BRIEF-Arcus Outlines Plans For Casdatifan And Its Inflammation Programs

Reuters
·
Jan 08

Arcus Biosciences Inc - Plans Three Data Readouts for Casdatifan in 2026

THOMSON REUTERS
·
Jan 08

Arcus Biosciences Inc - Expects to Fund Operations Until Second Half of 2028

THOMSON REUTERS
·
Jan 08

Arcus Biosciences President Juan C. Jaen Reports Sale of Common Shares

Reuters
·
Jan 08

Arcus Biosciences CFO Robert C. Goeltz II Reports Disposal of Common Shares

Reuters
·
Jan 03

Have Insiders Sold Arcus Biosciences Shares Recently?

Simply Wall St.
·
Dec 20, 2025

Arcus Biosciences President Juan C. Jaen Reports Sale of Common Shares

Reuters
·
Dec 19, 2025

Arcus Biosciences Inc - First Amendment Extends Maturity Date to Sept 1, 2030, With No Further Extension Right- SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Arcus Biosciences Inc - Amendment Changes Terms for $150 Mln Loan Commitments - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Arcus Biosciences Amends Loan Agreement to Access Up to $150 Million in New Financing

Reuters
·
Dec 19, 2025

Arcus Biosciences CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 19, 2025

Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Benzinga_recent_news
·
Dec 13, 2025

Arcus Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 13, 2025

BUZZ-U.S. STOCKS ON THE MOVE-EastGroup, Boeing, Exxon Mobil

Reuters
·
Dec 13, 2025

Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating

MT Newswires Live
·
Dec 13, 2025

BUZZ-U.S. STOCKS ON THE MOVE-ProPetro, Nvidia, Citigroup

Reuters
·
Dec 12, 2025

Arcus Biosciences Shares Down 12% Premarket After Co and Gilead Scrap Late-Stage Trial of Cancer Drug Combo

THOMSON REUTERS
·
Dec 12, 2025